跳转至内容
Merck
CN

EHU022341

MISSION® esiRNA

targeting human BCL9

登录 查看组织和合同定价。

选择尺寸

关于此项目

NACRES:
NA.51
UNSPSC Code:
41105324

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

MISSION® esiRNA, targeting human BCL9

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

TCACCTGGATGGACCTCTTCTCCAAAACCTCCCCTTCAGAGTCCTGGGATCCCTCCAAACCATAAAGCACCCCTCACCATGGCCTCCCCAGCCATGCTGGGAAATGTAGAGTCAGGTGGCCCCCCACCTCCTACAGCCAGCCAGCCTGCCTCTGTGAATATCCCTGGAAGTCTTCCCTCTAGTACACCTTATACCATGCCTCCAGAGCCAACCCTTTCCCAGAACCCACTCTCTATTATGATGTCTCGAATGTCCAAGTTTGCAATGCCCAGTTCCACCCCGTTATACCATGATGCTATCAAGACTGTGGCCAGCTCAGATGACGACTCCCCTCCAGCTCGTTCTCCCAACTTGCCATCAATGAATAATATGCCAGGAATGGGCATTAATACACAGAATCCTCGAATTTCAGGTCCAAACCCCGTGGTTCCGATGCCAACCCTCAGCCCAATGGGAATGACCCAGCCACTTTCTCACTCCAATCAGATGCCCTCTC

Ensembl | human accession no.

ENSG00000116128

NCBI accession no.

NM_004326

shipped in

ambient

storage temp.

−20°C

Quality Level

100

Gene Information

human ... BCL9(607), BCL9(607)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
QCS

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chao Yang et al.
Cell death & disease, 8(8), e2999-e2999 (2017-08-18)
Metastasis is the major cause of the poor prognosis of hepatocellular carcinoma (HCC), and increasing evidence supports the contribution of miRNAs to cancer progression. However, the exact relationship between the level of miR-1301 expression and HCC cell migration, invasion, and
Hanan S Elsarraj et al.
Breast cancer research : BCR, 17, 128-128 (2015-09-19)
There are an estimated 60,000 new cases of ductal carcinoma in situ (DCIS) each year. A lack of understanding in DCIS pathobiology has led to overtreatment of more than half of patients. We profiled the temporal molecular changes during DCIS

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持